Skip to main content
. 2021 Aug 15;18(3):910–930. doi: 10.20892/j.issn.2095-3941.2020.0511

Figure 2.

Figure 2

Basic Karanahan approach parameters and treatment schedule. (A) Results of the cell cycle assays in U87 cells prior to the treatment with MMC, 18, 54 and 90 h later as well as on days 6–9 after the first treatment. G1, S, and G2/M, phases of the cell cycle; subG1, apoptotic (presumably) cells. (B) Principle therapeutic scheme for treating U87 glioblastoma cells in vitro. Arrows indicate the appropriate timings for administration of cytostatic agent and composite DNAmix preparation. The dashed line displays the concomitant number of DSBs induced by the exposure of U87 cells to a cytostatic agent. (C) Percentage of TAMRA+ cells in U87 cell culture after treatments with MMC and DNAmix preparation according to the Karanahan approach. The average value ± 99% CI are given; confidence was estimated relative to the control using the Mann–Whitney criterion in the Statistica 10 software package, *P < 0.05. (D) Cytological preparations of U87 cells before (control) and on days 3, 7, and 15 since the start of therapy. The figure represents the merged image of DAPI (chromatin) and TAMRA (exogenous DNA) staining. For the control and MMC + DNAmix groups, images of cells in transmitting light are also given. MMC, group treated with cytostatic only; MMC + DNAmix, group treated with cytostatic in combination with DNA-based preparation.